amit k. tiwari, ph.d. - biomedical and pharmacology...

AMIT K. TIWARI, Ph.D. HEB-282F, Frederic and Mary Wolfe Center, Department of Pharmacology Experimental Therapeutics, College of Pharmacy & Pharmaceutical Sciences, Health Science Campus,

The University of Toledo, 3000 Arlington Ave., MS 1015; Toledo, OH 43614 Tel: (419) 383-1913; Fax: (419) 383-1909; Email: [email protected]

ACADEMIC APPOINTMENTS

2015-Present Principal Investigator, Assistant Professor of Pharmacology Dept. of Pharmacology & Experimental Therapeutics, College of Pharmacy &

Pharmaceutical Sciences, Health Science Campus, University of Toledo, 3000 Arlington Ave., Toledo, OH 43614

2013-2015 Assistant Professor of Pharmacology and Toxicology Dept. of Biomedical Sciences, CVMNAH, Tuskegee University, Tuskegee, AL 36088 2011-2013 PostDoctoral Fellow, (Advisor: James M. Gallo, PhD)

Department of Pharmacology and System Therapeutics, Mount Sinai School of Medicine, NY, NY 10029

2012-2013 NYAS Fellow, New York Academy of Sciences Alliance, NY 2010-2011 University Fellow, College Of Pharmacy And Health Sciences, St. John’s University, Queens, NY 11439 2010 Research Fellow, ZS Chen’s lab, (Summer semester) College Of Pharmacy And Health Sciences, St. John’s University, Queens, NY 11439 2008-2010 Teaching Fellow, College Of Pharmacy And Health Sciences, St. John’s University, Queens, NY 11439 2007-2008 Teaching Assistant, College Of Pharmacy And Health Sciences, St. John’s University, Queens, NY 11439

INDUSTRIAL APPOINTMENTS

2005 – 2006 Nutrition Officer, Nestle Ltd., New Delhi, India. 2004 - 2004 Intern, Zydus Cadilla Healthcare Ltd., Gaziabad, U.P, India.

EDUCATION

2008 – 2011 Ph.D., College of Pharmacy and Health Sciences, St. John’s University, Queens, NY

Major: Pharmaceutical Sciences: Pharmacology (GPA - 3.9/4.0) Advisor: Z.S. Chen, M.D, Ph.D

2006 – 2008 Master of Science, College of Pharmacy and Health Sciences, St. John’s University, Queens, NY

Major: Pharmaceutical Sciences: Pharmacology (GPA - 3.7/4.0) Advisor: Z.S. Chen, M.D, Ph.D 2001- 2005 Bachelor of Pharmacy,

Ram-Eesh Institute, G. Noida, U.P.T.U Univ, India Major: Pharmaceutical Sciences (GPA - 4.0/4.0)

Amit K. Tiwari, Ph.D. C.V. P a g e 2

AWARDS AND ACHIEVEMENTS

2016 Learner Engagement Award, College of Pharmacy, University of Toledo, Ohio

2016 Outstanding Scientist - Excellence in Innovation Research Award, MP, India

2015 ASM-LINK Undergraduate Research Initiative Fellowship Award from NSF/ASM

2015 Travel award, ABRCMS conference, Seattle, Washington

2014 Health Disparity Research Summer Institute, Al, Travel and 2nd Best Poster Award

2014 Travel award, ABRCMS conference, San Antonio, TX

2014 Travel Award, GMaP conference, Johns Hopkins, Bethesda, MD

2013 Top citation Award from FEBS journal 2011-2013

2013 US Permanent residency in EB1A (Aliens with extraordinary ability) category

2012 New York Academy of Science (NYAS) Alliance Fellow

2012 Honored as Pharmacy School Marshal at St. John’s University, NY 2012

commencement event.

2011 The story of my achievements published on the St. John’s University home page

2011 Outstanding performance in Research Award - St. Johns University, NY

2010 University Fellowship, St. Johns University, NY

2010 Ray-Biotech 2010 Biomarker Grant, Co-PI, while being graduate student

2010 Excellence Award for Research in 2009 at Cancer Lab’s, St. John's University, NY

2009 Tiwari et al (2009). Nilotinib (AMN107, Tasigna) reverses multidrug resistance by

inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters.

Biochem Pharmacol” was 5th and 4th hottest article in Science Direct from April –

Sept 2009. (http://top25.sciencedirect.com/subject/pharmacology-toxicology-and-

pharmaceutical-science/20/journal/biochemical-pharmacology/00062952/archive/22/)

2009 Top citation award from Elsevier – Tiwari et al. 2009, Biochem Pharmacology

2007 - 2011 Full scholarship with tuition waiver and stipend from St. John's University for

both M.S. and PhD

http://top25.sciencedirect.com/subject/pharmacology-toxicology-and-pharmaceutical-science/20/journal/biochemical-pharmacology/00062952/archive/22/



RESEARCH FUNDING

Completed

1. Ray-Biotech –Pilot-Biomarker grants - 3-10 to 2-13 Title: Identify biomarkers of resistance or response to anti-EGFR therapy of cancers Role - Tiwari AK, Co-Principle Investigator Direct costs: $20,000

2. Morehouse School of Medicine/Tuskegee University/ Univ. Of 3-14 to 2-15

Alabama at Birmingham Comprehensive Cancer Center Partnership U54 grant – pre-pilot projects - Title: The role of TTP-Lin28-let-7-axis in the regulation of colorectal cancer treatment Role - PI (Tiwari AK) Direct costs: $15,000

3. UAB MHRC- Health Disparities Research Training Program Grant 2014 2-14 to 2-15

Title: Role of ABCC family of transporters and their signaling pathway in the regulation of chemotherapy responses in pancreatic cancers Role - PI (Tiwari AK) Direct costs: $10,000

4. California Grape Commission - 8-14 to 7-15

Title: Effects of Whole Grape Powder on NF-kB driven inflammatory signaling Role – Co-PI (Tiwari AK); PI (Samuel T) Direct costs: $30,000

Accepted for funding but withdrawn 1. NIH - U54 grant – pilot project - Accepted 10/14

Title: Targeting mitochondria in triple negative breast cancer Role - PI (Tiwari AK) Direct costs: $230,000

*Award Accepted for funding but the PI has to decline due to job change from Tuskegee to Univ of Toledo; grant was non-transferrable.

Active 1. University of Toledo - Start-up Funds 3-15 to 2-20

Pending/Resubmitting Research Support 1. National Science Foundation – MRI Grant

Role - Tiwari AK, PI Title: MRI: Acquisition of Multispectral Optoacoustic Tomography Next-GEN Imaging for Multidisciplinary Life Sciences Research and Training Amount: $1.06 million; Outcome: Meritorious; Not Funded


2. NIH – RO-1 Role - Tiwari AK, Co-PI; NK Narayanan, NYU (PI) Title: Modulation of NK cell-antitumor efficacy against Prostate Cancer by Melinjo Seeds Amount: $2.5 million; Outcome: Unscored – Revising and resubmitting

3. NIH – 21 Role - Tiwari AK, PI; Singh K, UAB (Co-PI) Title: Pharmacological assessment of TNBC targeted dynamin related protein-1 antagonists Amount: $397,450; Outcome: Not Funded

4. NIH – R-15 Role - Tiwari AK, Co-PI; Chauhan H, Creighton Univ (PI) Title: Prediction of the Hepatotoxicity of Dietary Supplements by Means of Machine-Learning Amount: $278,000; Outcome: Scored, Not Funded – revising resubmitting

5. NIH – R-15 Role - Tiwari AK, PI Title: Targeting chemoresistant colon cancer with plant- derived synthetic analogues that inhibit embryonic signaling pathways Amount: $450,988; Outcome: Not Funded – revising resubmitting

6. Dominican Republic – MESCyT Role - Tiwari AK, PI; Terrero D, Colead-PI Title: Anticancer activities of Fevillea cordifolia and its active constituents Amount: $195,000; Outcome: Not Funded – revising resubmitting

7. NIH – R-15 Role - Tiwari AK, Co-PI; Chauhan H, Creighton Univ (PI) Title: Ionically Complexed and Miscible Food Supplements-Delivery Matrices as Safe and Potent Anticancer Pharmaceuticals Amount: $278,000; Outcome: Not Funded – revising resubmitting

8. NIH – R-15 Role - Tiwari AK (PI) Title: Targeting embryogenic signaling pathways in colon cancer Amount: $378,453; Outcome: Not Funded – revising resubmitting

9. NIH – R-03 Role - Tiwari AK (PI) Title: Pharmacological assessment of TNBC targeted dynamin related protein-1 antagonists Amount: $149,470; Outcome: Not Funded – revising resubmitting

10. AACP Foundation Role - Tiwari AK (PI) Title: Targeting mitochondrial dynamics for novel TNBC therapy Amount: $100,000; Outcome: Not reviewed, resubmitting


PROFESSIONAL SERVICES/ACTIVITIES

2017 Reviewer, INBRE-DRPP Grant

2016-17 Judge and Reviewer, MGRS Conference, Toledo, OH

2016 Thesis Reviewer, MRES Higher education, Macquaire Univ, Australia

2016 Reviewer, Medical Research Council, UK-ASM Newton Grant Panel

2015-16 Reviewer, NSF-GRFP Grant Panel

2015 Judge and Reviewer, Oral and Poster presentation, ABRCMS conference,

Seattle, Washington

2015 Judge, Graduate Research Council, University of Toledo

2014 Judge and Reviewer, NSF-GRFP Panel

2014 -15 Judge and Reviewer, Oral & Poster session, ABRCMS, San Antonio, TX

2014 –15 Grant Reviewer, Macquarie University Research Fellowships 2015,

Australia

2014 - 15 Chair –CPCE committee, School of Veterinary Medicine, Tuskegee Univ.

2014 –15 Leader – RCMI Translational Research Network (RTRN) Genes, Environment and Toxicology cluster.

2014 Haitian-Tuskegee Training Research Committee; Major Prof - Toxicology 2013 Judge and Reviewer– Abstracts for Annual Biomedical Research

Conference for Minority Students (ABRCMS), Nashville, Tennessee, 2013 2013 Judge – Oral session, Phi Zeta Research Day, 14th Biomedical Research

Symposium, Tuskegee University, Tuskegee, Sept. 20, 2013 2013 Judge – NanoBio Summit, Center for Nanobiotechnology Research,

Alabama State University, Oct. 17-18, 2013, Montgomery, AL

2013 - present Editor: Translational Clin Biol; Cell Signaling; J of Medicinal Chem & Tox

2012 –present Associate Editor-in-Chief - Journal of Post-Doctoral Research (JPR)

2012 –13 NYAS Fellow - volunteered to teach elementary school students in

Afterschool STEM Program

2011-12 "Work in Progress" committee and “Pharmacology and Systems Biology

Retreat” Organizing Committee in the Dept. of Pharmacology and Systems

biology, Mount Sinai School of Medicine, NY (Nov. 2011 – Aug. 2012)

2012 –present Editor - J. of Life Sciences; Editor - Int. J. of Pharmaceutical Res. and Bio-

Science (IJPRBS)

2010 -present Senior Scientific committee advisor, Institute of Transgene Life Sciences, India

2010 –present Active Editorial Group Member “Current trends in biotechnology and pharmacy”

2010 - present Elected Editorial Board member of 10 prestigious journals and appointed as journal referee of more than 50 peer-reviewed journals


Committees Serving (University of Toledo): a. University of Toledo:

1. Assessment Committee, CPPS (Feb 2015 – present) 2. Faculty Senate Constitution and Rules Committee, UT (Oct 2015 – present) 3. LGBTQ Committee, UT (Nov 2015 – present) 4. Health Disparity Committee, CPPS (July 2015 – present)

b. National and International:

1. AACP Health Disparities and Cultural Competency Nominations Committee (Nov.

2015 – present) 2. AACP Biological section: Chalmers, the Dawson and the Volwiler awards committee

2. Research Innovations Committee, RGVP, Bhopal, India (Jul 2015 – present) 3. External Scientific Committee, Institute of Transgene Life Sciences, India (2010-present) c. Grant reviewer

1. NSF-GRFP 2014-2016 2. Macquarie University Research Fellowships 2015, Australia 3. Medical Research Council, UK – Reviewed - UK-ASM Newton Fund Proposal, 2016

Committees Served a. Tuskegee University:

1. Integrated Biosciences (IBS) PhD Advisory Committee:

a. Floyd Davis (PhD – expected 2015)

b. Dominique Gales (PhD – expected 2016)

c. Amina Wafford (PhD – expected 2017)

d. Crystal Lee (PhD – expected 2018)

e. Anusha Angajala (PhD – expected

2. Interdisciplinary Pathobiology PhD Advisory Committee:

a. Roopak Chowdhary (PhD – expected 2016)

b. Mhaer Thalal (PhD – expected 2018)

3. Cultural Organizing Committee – 14th Biomedical Symposium, TU

4. CVNAH, TU Research Committee – AVMA/COE

5. Class of 2016 Faculty Advisor – College of Veterinary Medicine, TU

6. Haitian-Tuskegee Training Research Committee: Served as a Major Professor -

Toxicology to Samuel Raphael (Haitian Trainee) for 8 weeks. (01-15-2014 – 03-15-14)

7. Leader –RTRN, Genes, Environment and Toxicology cluster

8. Tuskegee Biomedical Symposium Committee (07-2013 – 2-2015)

9. Chair –CPCE committee, School of Veterinary Medicine, Tuskegee Univ. (03-2014 – 2-

2015)

10. Phi-Zeta Research Committee (04-2014 to 2-12015)

11. Health and Safety Committee, TU (08-2014 to 2-2015)


Current Professional Affiliations

2008 – present American Association for Cancer Research (AACR) 2009 – present American Cancer Society (ACS) 2011 – present New York Academy of Sciences (NYAS) 2011 – present American Association for the Advancement of Science (AAAS) 2012 – 2013 American Association of Pharmaceutical Sciences (AAPS) 2015 – present American Association of College of Pharmacy (AACP) 2015 – present American Association of University Professors (AAUP)

Editor and Associate Editor

Editor - J. of Life Sciences – (http://jexpsciences.com/index.php/jexp/pages/view/editorial_board) Editor - Int. J. of Pharmaceutical Res. and Bio-Science (IJPRBS)

(http://www.ijprbs.com/editorialboard.php) Editor – Translational Clinical Biology (http://vedicjournals.com/index.php/CS) Editor - VRI Cell Signaling (http://vedicjournals.com/index.php/CS) Associate Editor: Frontiers in Pharmacology Associate Editor: Frontiers in Oncology Associate Editor-in-Chief - Journal of Post-Doctoral Research (JPR) (2012 – 2014) (http:/www.postdocjournal.com/editorial-board.aspx?s=jpr)

Editorial Board Member

J. of Investigational Biochemistry Frontiers in Pharmacology Current Clinical Pharmacology J. Analytical Oncology; Pharmacy and Pharmacology Int. Journal Journal of Medicinal Chemistry & Toxicology Int. J. of Toxicological and Pharmacological Res. (IJTPR) Achieves of Pharmacy Practice Annals of Clinical Case Reports SM Pharmacology & Therapeutics Austin Pharmacology & Pharmaceutics Modern Chemotherapy Biomedical & Pharmacology Journal International Journal of Hospital Pharmacy Int. J. of Pharmaceutical and Clinical Research (IJPCR)

Journal Refree

1. Oncogene 2. Clinical Cancer Research 3. Oncotargets 4. Biochemical Pharmacology 5. Cellular Physiology and Biochemistry 6. Drug Discovery Today 7. Molecular Metabolism

http://jexpsciences.com/index.php/jexp/pages/view/editorial_board

http://www.ijprbs.com/editorialboard.php

http://vedicjournals.com/index.php/CS

http://vedicjournals.com/index.php/CS

http://www.postdocjournal.com/editorial-board.aspx?s=jpr


8. J of Cellular and Molecular Medicine 9. J. Cancer Therapy (JCT) – Review Editor 10. J. Experimental Pharmacology (JEP) 11. Current Clinical Pharmacology (CCP) 12. Clinical Pharmacology: Adv. and Applic (CPAA) 13. J. Cancer Research Updates (JCRU) 14. J. of Animal Production Advances (JAPA) 15. J. Of Exp. Therap. & Integrat Med. (JETIM) 16. J. Of Pharmacy and Nutrition (JPN) 17. J. Of Pharmacy and Bioallied Sci. (JPBS) 18. The J. of Medicinal Plant Research (JMPR) 19. Therap. and Clinical Risk Management (TCLRM) 20. Cancer Management and Research (CMR) 21. Current Neuropharmacology (CN) 22. Oncotargets and Therapy 23. American J. Of Mol. Biol – Review Editor 24. Pharmacogenomics and Personalized Medicine 25. Bioinorganic Chemistry and Application 26. Stem Cells And Cloning: Advances & Applications 27. Molecular Medicine Reports 28. Expert Review of Anticancer Therapy 29. Cancers 30. BMC Cancer 31. Cellular Biochemistry 32. Antibiotics 33. Molecules 34. American J of Cancer Research 35. Chinese Journal Of Cancer (CJC) 36. Leukemia Research (LR) 37. Marine Drugs 38. Cancer Chemotherapy & Pharmacology 39. Medicinal Chemistry Communications 40. Pharmaceutica Analytica Acta 41. Metal Based Drugs (MBD) 42. J. Microbiology and Infectious Disease 43. Frontiers in Pharmacology 44. J. Of Analytical Oncology (JAO) 45. PLoS One 46. Nutrition and Cancer 47. J. of Investigational Biochemistry (JIB) 48. Molecular Cancer Biology 49. J. Of Microbiology And Infectious Diseases 50. J. Of Cellular and Molecular Medicine 51. Onco-Reviews 52. J. Of Bacteriology Research (JBR) 53. African J. Of Microbiology Res. (AJMR) 54. Expert Opinion On Therapeutic Patents 55. Drug Discoveries & Therapeutics (DDT) 56. Pharmacology and Pharmacy International (PPI) 57. VRI Cell Signaling 58. Expert Opinion In Metabolism And Toxicology 59. Drug, Design, Development & Therapy 60. J. of Animal Science Advances (JASA) 61. Cell Signaling (VRI publications) 62. Toxicology & Applied Pharmacology


63. Chemical Research in Toxicology 64. Medical Science Monitor 65. Cancer Therapy & Biology 66. Scientific Reports – Nature Press 67. Indian J of Pharmaceutical Sciences 68. Springer Plus 69. Journal of Natural Products 70. Pharmacology & Pharmacy International 71. Gene reports 72. Nutrients 73. MDPI cancer 74. Aging 75. BMC Complimentary & Alternative Medicine

TEACHING EXPERIENCE

ST. JOHN’S UNIVERSITY

Teaching Fellow, 08/2008 – 07/2010 Taught molecular biology laboratory courses including Pharmacology, Biochemistry, Oncology, Cardiovascular, Immunology, Endocrinology and Compounding laboratory courses to graduate pharmacy students (2nd – 5th year) from (2008 – 2010; including summer sessions)

Managed class and lab of 85 students/term, while supervising a team of 4 assistants

Teaching Assistant, 08/2007 – 08/2008 Experience in assisting undergraduate pharmacy labs Pharmaceutical compounding; Parenteral preparations; Pharmacogenetics

TUSKEGEE UNIVERSITY – ASSISTANT PROFESSOR

TERM COURSE NUMBER

SUBJECTS SPECIFIC STUDENTS

Fall 2014

PHSI.0442.01.13FA:

Pharmacology PK/PD, Immunosuppressant’s, Biologic modifiers, Cardiovascular, GI, Respiratory 75

Fall 2014

NURS 0314; Pharmacology

Pharmacology Pharmacology basics, ANS, CNS, Onco-pharmacology, Respiratory, Cardiovascular, Pharmacogenetics 25

Spring 2014

PHSI.0543.01.14SP:

Pharmacology Antimicrobial agents, Anticancer therapeutics, Neuropharmacology 76

Spring 2014

PHSI.0546.01.14SP:

Toxicology Toxicokinetics,Metal toxicity, Mycotoxins, Zootoxins, Herbicides 74

Fall 2013

PHSI.0442.01.13FA:

Pharmacology Pharmacometrics, Pharmacogenetics, PK/PD, Cardiovascular, GI, Endocrinology, Corticoids, Respiratory drugs, 76


UNIVERSITY OF TOLEDO– ASSISTANT PROFESSOR

I joined the Pharmacology Department in the late spring of 2015. I have spent majority of my time in summer laboratory instructions, setting the assays/Labs, preparing and disseminating lectures for PHCL 4140/5140; PHCL-5100/7100; PHCL-4700; PHCL3730/5720; PHPR 5770; PHCL6600; PHCL-5500/7500. Course evaluations by students are extremely encouraging and productive.

a. Co-taught with Jeff Sarver, Scott Hall and Caren Steinmiller; b. Co-taught with Scott Hall; c. Co-taught with Ezdihar Hassoun; d. Co-taught with Ana Oyarce, Wissam Aboualaiwi; e. Co-taught with Yousef Sari, Jeff Sarver; f. Co-taught with Sai Boddu; I now serve as a course coordinator for PHCL-4700 with majority of the course responsibility and am currently working to develop new assessment and lectures for the course.

Classroom teaching assessment: Some examples of student assessment in different student populations: PharmD - PHCL4700: Pharmacol II: CNS Endocrine and Pharmacology (Fall 2016) “Slide content and quality is good, and the online google forms help to solidify where I stand on knowledge based material. Also, it helps to get an idea of how you ask questions on exams and in what style they are written.” “Dr. Tiwari, you are awesome! Your lectures are so clear and easy to follow.” “I like how you are passionate about teaching this topic, it keeps us engaged.” “I like the style. Having sample questions to access what we know is very helpful.” “feel engaged during lecture material. enjoy the diagrams and repetitive content presented in different ways to ensure that we understand concepts” “The lecture quality has been very good! I feel like it is important to spend a lot of time going through the details of each slide and that has been sufficient thus far. Also I think feedback questions like this that test your knowledge of the material is helpful as well.” MS and PhD – PHCL5100/7100; PHCL5500/7500 (Fall 2016) “I love colors, but sometimes the contrast makes it hard to read. I think the blue background needed to be much darker or lighter and darker lettering. As for the actual lecture, it was great! I feel like I understand the concepts and it is very interesting. The explanations are very relatable and clear.” “The graphs were helpful in understanding the lecture” “It was very neatly put together. Well delivered. You explained well the complex ideas” “Honestly, best lecturer in this class to date. It was new material presented in a useful and thought provoking manner. The slides were clear and discussing one thing helped to clarify the points.” BSPS – PHCL3700: (Spr 2015) “This was my first time ever having Dr. Tiwari as a professor and I was thoroughly impressed! He seemed so passionate about what he was teaching (although later I found he didn't care for the material he taught). He was phenomenal at teaching us at 8am and not making students fall asleep. He really pushed for student interaction too. I think the reason why I remember so much from his course is because of how he presented it. I would love to see Dr. Tiwari teach more courses, he did a fantastic job!” “Dr. Tiwari was a great instructor his use of examples and graphs was very pivotal to my learnering experience” “Much of Dr. Tiwari's material was introducing new topics to us, but relied on the pharmacokinetic and pharmacodynamic properties taught to us last semester in PHCL 3700. Dr. Tiwari did a good job of introducing these topics in a way that related back to what we had previously learned.”

Course no. Title Credits Term Students Lecture/Hrs

PHCL-4140/5140a Interpretation of Pharm Data 3 Su, 15 12 1 (3h)

PHCL-5100/7100b Experimental Therapeutics I 3 Fall,15 8 1 (1.5h)

PHCL-6600c Seminars in Pharmacology 1 Fall,15 5 1 (1h)

PHCL3730/5720e Pharmacol II: CNS Endocrine

and Pharmacology3 Spr, 15 105 10 (1h)

PHPR 5770f Advanced Drug Delivery

Systems-I3 Spr, 15 24 1 (2h)

PHCL3730/5720e Pharmacol II: CNS Endocrine

and Pharmacology3 Fall, 16 103 12 (1h)

PHCL-6600c Seminars in Pharmacology 1 Fall, 16 3 1 (1h)

PHCL-5100/7100b Experimental Therapeutics I 3 Fall,16 5 1 (1.5h)

PHCL-5500/7500c From Experimental to Appl Therap 4 Fall,16 5 1 (2h)


LAB INSTRUCTIONS:

Semester Course no. Course Students Level Credits

Contact

Hrs/week

1 PHCL4960 Honors Thesis in Pharmacology Vandress Arantes** BS - international 2 5

2 PHCL4780 Internship in Pharm-Toxicology Joel Chen* BSPS - P2 6 7

3 PHCL4780 Internship in Pharm-Toxicology Erin Kirwen* BSPS - P2 6 8

4 PHCL4780 Internship in Pharm-Toxicology Amy Nusbaum* BSPS - P2 6 7

1 PHCL2900 Pharmacology Research Intro Rohit Kumar Sophomore 2 2

2 PHCL4780 Internship in Pharm-Toxicology Jenna Christman* BSPS-P2 6 3

3 PHCL4910 Problems in Pharmacology Ryann Christman BSPS-P1 2 1

4 PHCL4910 Problems in Pharmacology Joel Chen BSPS - P2 3 2

5 PHCL4910 Problems in Pharmacology Erin Kirwen BSPS - P2 1 1

6 PHCL4910 Problems in Pharmacology Amy Nusbaum BSPS - P2 3 2

7 PHCL8300 Research Exp in Experimental Kyle McIntosh PhD 3 3

8 PHCL8300 Research Exp in Experimental Angelique Nyinawabera PhD 3 3

9 PHCL 8960 Dissertation Res in Exp Therap Haneen Amwai PhD 2 3

1 PHCL6300 Research Exp in Exper TherapeuticsHaneen Amawi PhD 6 4

2 PHCL5900 Problems in Pharmacology Angelique Nyinawabera PhD 4 2

3 PHCL8960 Dis Research in Exper TherapeuticsHaneen Amawi PhD 3 1

4 PHCL6390 Problem in Experimental TherapeuticsHaneen Amawi PhD 2 1

5 PHCL6390 Problem in Experimental TherapeuticsKyle McIntosh PhD 2 4

6 PHCL4910 Problems in Pharmacology Xuexuan Xu BSPS-P1 3 3

7 PHCL5900 Problems in Pharmacology Noor Hussein MS 3 4

8 PHCL6920 MS Thesis Research - Pharmacol Noor Hussein MS 6 3

9 PHCL2900 Pharmacol Research Intro Rohit Kumar Sophomore 1 1

1 PHCL4780 Internship in Pharm-Toxicology Aubry E. Fetcenko* BSPS - P1 6 3

2 PHCL5900 Problems in Pharmacology Joshua Staffeld Pharm D - P2 2 2

3 PHCL6920 MS Thesis Research - Pharmacol Noor Hussein MS 1 1

4 PHCL8300 Research Exp in Experimental Haneen Amawi PhD 4 25 PHCL8390 Problems in Exp Therapeutics Kyle McIntosh PhD 3 3

6 PHCL 8960 Dissertation Res in Exp Therap Haneen Amwai PhD 5 4

Fall, 2016 1 PHCL 4780 Intern in Pharm-Toxicology Ryann M. Christman* BSPS - P2 6 3

2 PHCL 4910 Problems in Pharmacology Aubry E. Fetcenko* BSPS - P2 1 1

3 PHCL 4910 Problems in Pharmacology Mahmood Meqdad BSPS - P2 1 1

4 PHCL 6900 MS -Thesis Res - Pharmacology Noor Hussein MS 1 3

5 PHCL 8300 Research Exp in Experimental Kyle McIntosh PhD 2 4

6 PHCL 8390 Problems in Exper Therap Haneen Amawi PhD 4 2

7 PHCL 8960 Dis Research in Exp Therap Haneen Amawi PhD 3 2

8 PHCL 8960 Dis Research in Exp Therap Nyinawabera, Angelique PhD 3 3

Fall, 2015

Su, 2015

Spr, 2016

Su, 2016


PEER-REVIEWED PUBLICATIONS

Notes: # Sum of times cited (as of 02.01.2017): 1690| Average citations per item: 33.80

|h-index: 18.0 | i-10 index: 21.0

Book Chapters

1. Shi Z*, Tiwari AK*, Ashby CR, Fu LW and Chen ZS. Anticancer role of Phospodiesterase 5 inhibitors. The Research and Biology of Cancer I. ISBN: 978-1-477554-999. (*Joint-First Author).

2. Tiwari AK#, Yang DH, and Chen ZS. Molecular mechanisms of methotrexate resistance.

Nova Science Publishers, Inc. ISBN – 978-1-62100-596-4, 2012

3. Mittal R, Agrawal A, Tourne M, Koduru SV, Viana AG, Reddy G, and Tiwari AK#.

Nanoparticle-Based Therapeutics to Circumvent Cancer Chemoresistance. NanoBiomedicine: Nanostructured Drug Delivery. 2015, Vol. 4, Pages 383-408, Studium Press LLC, USA; ISBN: 1-62699-054-9, 2015

Research and Review Articles

4. Sirohi S and Tiwari AK. Pain in the management of opioid use disorder. J of Pain

Research, 2016 (accepted, in press)

5. Koduru SV, Tiwari AK, and Ravnic DJ. A Comprehensive NGS Data Analysis of

Differentially Regulated miRNAs, piRNAs, lncRNAs and sn/snoRNAs in Triple

Negative Breast Cancer. J of Cancer, 2017, (accepted, in press)

6. Koduru SV, Tiwari AK, Hazard SW, Mahajan M, Ravnic DJ. Comprehensive analysis of

non-coding small RNAs in human colorectal cancer. Oct, 2016 (Revision- under review –

J of genes and genetics)

7. Ferretti M, Saji A, Mittal R, and Tiwari AK. Infectious complications following prostate

biopsy: a single institution review. J of Cancer Research Upd, 2016 (accepted, in press)

8. Kirwen EM, Batra T, Karthikeyan C, Deora GS, Vathore V, Mulakayalae C, Mulakayala

N, Nusbaum AC, Joel Chena, Amawi H, McIntosh K, Sahabjada, Arantes V, Shivnath N,

Chaurasia D, Sharma N, Md Arshad , Trivedi P and Tiwari AK. 2,3-Diaryl-3H-

imidazo[4,5-b]pyridine derivatives as potential anticancer & anti-inflammatory agents.

Acta Pharmaceutica Sinica B, 2016

9. McIntosh K, Balch C and Tiwari AK#. Tackling multidrug resistance mediated by efflux transporters in tumor initiating cells. Expert Opinion in Drug Metabolism and Toxicity, 2016

10. Hussain S, Sulaiman A, Balch C, Chauhan H, Alhadidi Q and Tiwari AK#. Natural polyphenols in cancer chemoresistance. Nutrition and Cancer, 2016


11. Karthikeyan C, Malla R, Ashby CR Jr, Amawi H, Abbott KL, Moore J, Chen J, Balch C, Lee C, Flannery PC, Trivedi P, Faridi J, Pondugula SR, and Tiwari AK#.

Pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells. Cancer Lett. 2016 Mar 21. pii: S0304-3835(16)30180-X. doi: 10.1016/j.canlet.2016.03.030. PMID: 27012188

12. Narayanan NK, Kunimasa K, Miller G, Tiwari AK and Narayanan B. Antitumor activity of melinjo (Gnetum gnemon L.) seed extract in human and murine tumor models in vitro and in a colon 26 tumor-bearing mouse model in vivo. Cancer Medicine, 2015

13. Malla R, Wang Y, Chan W, Tiwari AK, Faridi JS. Genetic ablation of PRAS40 improves glucose homeostasis via linking the AKT and mTOR pathways. Biochem Pharmacol. 2015 Apr 27. pii: S0006-2952(15)00239-7. doi: 10.1016/j.bcp.2015.04.016. (Cited 7 times: as of 08-01-16)

14. Hassan H, Min BJ, Tiwari AK, Reddy GP, Hinton A, Adesiyun A and Abdela W. Antibacterial activity of plant extracts against food-borne pathogens and spoilage bacteria. International Journal of Poultry Science 14 (x): xx-xx, 2015

15. Malla R, Ashby CR, Narayanan N, Narayanan B, Faridi JS, and Tiwari AK#. Proline-rich AKT substrate of 40-kDa (PRAS40) in the pathophysiology of cancer: Biochemical Biophysical Research Communications, 2015, (Cited 13 times: as of 08-01-16)

16. Pondugula SR, Ferniany G, Ashraf F, Abbott KL, Smith BF, Coleman ES, Mansour M, Bird RC, Smith AN, Karthikeyan C, Trivedi P, Tiwari AK. Stearidonic acid, a plant-based dietary fatty acid, enhances the chemosensitivity of canine lymphoid tumor cells. Biochemical Biophysical Research Communications, 2015 (Cited 2 times: as of 08-01-16)

17. Balaji NV, Ramani MV, Viana AG, Sanglard LP, White J, Mulabagal V, Lee C, Gana TJ, Egiebor NO, Subbaraju GV and Tiwari AK#. Design, Synthesis and In Vitro Cell-based Evaluation of the Anti-cancer Activities of Curcumin and Hispolon Analogs: (Bioorganic Medicinal Chemistry, March 2015)

18. Narayanan NK, Tiwari AK, Kunimasa K, Ashby CR, Narayanan B. Potential Role of Natural Dietary Compounds in the Modulation of Metabolomic Fingerprints of Cancer. Metabolomics , 2014, 5: e131. doi:10.4172/2153-0769.1000e131

19. Chandrabose K, Lee C, Moore J, Mittal R, Suswam EA, Abott KL, Pondugula SR, Manne U, Trivedi P and Tiwari AK#. Novel Pyrimido[1 ,2 :1,5]-pyrazolo[3,4-b]quinolines derivative circumvents multi drug resistance and produces potent apoptosis in colon cancer cells. (Accepted, in press Nov, 2014, Bioorganic Medicinal Chemistry) (Cited 7 times: as of 08-01-16)

20. Mansour AM, Abbott KL, Flannery PC, Coleman ES, Tiwari AK, Pondugula SR. Diindolylmethane Inhibits the Activity of P-glycoprotein in 17-71 Canine B-Cell Lymphoid Tumor Cells (Accepted, in press Nov, 2014, The Auburn Univ J of Undergrad Scholarship)

21. Sodani K, Tiwari AK, Dai, CL, Abuznait AH, Xiao ZJ, Patel A, Ashby C, Kaddoumi A and Chen ZS. Sildenafil enhances the anticancer activity of paclitaxel in an ABCB1-


mediated multidrug resistance xenograft mouse model. Journal of Cancer Research Upd, 2014, 3, 169-173

22. Guo H, Wang DS, Rizwani GH, Ahmed M, Ahmed M, Hassan A, Xu RH, Mansoor N, Tiwari AK and Chen ZS. Antineoplastic activity of Holoptelea integrifolia (Roxb.) Planch bark extracts (in vitro). Pak. J. Pharm. Sci., Vol.26, No.6, November 2013, pp.1151-1156 (Cited 3 times: as of 08-01-16)

23. Tiwari AK# and Koduru SV. Translating Mechanistic Knowledge of Diseases in Clinical Treatment. Trans Clin Bio, 2013; Volume 1 (Issue 1): Pages 1-2

24. Mittal R, Agrawal A, Roach R, Buckley T and Tiwari AK#. Acquired Legionnaire’s Disease through Aerosolization of Water from Natural Sources. Trans Clin Bio 2013; Volume 1 (Issue 1): Pages 6-9.

25. Williams A, Crawford L, Tiwari AK, Samuel T, Wirtu G. Lipid Metabolism in Mammary Neoplasia and Potential Therapeutic Targets. VRI Cell Signaling 2013; Volume 1 (Issue 2): Pages 16-21

26. Singh S, Makwana DK, Buckley T, Agrawal A, Koduru SV and Tiwari AK#. Clinical Significance of PARP-1 Inhibitors in Cancer Chemotherapy. Trans Clin Bio 2013; Volume 1 (Issue 1): Pages 10-15.

27. Chen JJ, Sodani K, Xiao ZJ, Tiwari AK, Patel A, Yang DH, Chen SD and Chen ZS. BBA, a synthetic derivative of 23-hydroxybutulinic acid, reverses multidrug resistance by inhibiting the efflux activity of MRP7 (ABCC10). PLoS One. 2013 Sep 17;8(9):e74573. doi: 10.1371/journal.pone.0074573. (Cited 7 times: as of 08-01-16)

28. Tiwari AK. Cell signaling to systems biology. Editorial, July 1st, 2013 p.1-2, Vol.1, VRI Cell signaling

29. Tiwari AK#, and Chen ZS. Repurposing PDE5 inhibitors as a chemoadjuvants. (June 25th, 2013, Frontiers in Pharmacology) (Cited 2 times: as of 08-01-16)

30. Chitranshi N, Tiwari AK, and Tripathi PK. Investigating the function of single nucleotide polymorphism (SNPs) in CTSB gene (cathepsin B): a computational approach. (Accepted May 18th, Future Neurology) (Cited 2 times: as of 08-01-16)

31. Patel A, Tiwari AK, Chufan EE, Sodani K, Anreddy N, Singh S, Ambudkar SV, Stephani R and Chen ZS. PD17384, human VEGFR inhibitor, reverses ABCB1 mediated drug resistance in cancer cells. (May 15th, 2013, Cancer Chemotherapy and Pharmacology) PMID: 23673445 (Cited 24 times: as of 08-01-16)

32. Tiwari AK, Zhang R and Gallo JM. Overlapping functions of ABC transporters in topotecan disposition as determined in gene knockout mouse models. (online first, May 1, 2013 Mol Cancer Ther) PMID: 23635651 (Cited 8 times: as of 08-01-16)

33. Tiwari AK, Sodani K, Dai CL, Abuznait AH, Singh S, Xiao ZJ, Vispute S, Patel P, Talele TT, Fu LW, Kaddoumi A, Gallo JM, Chen ZS. Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft


models. Cancer Lett. 2012 Oct 9. [Epub ahead of print] PMID: 23063650 (Cited 45 times: as of 08-01-16)

34. Kuang YH, Patel J, Wu CP, Sodani K, Dai CL, Tiwari AK, Lee J, Fu LW, Ambudkar SV, Korlipara V, Chen ZS. OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance. Biochem Pharmacol, 2012 Sep 15;84(6):766-74. PMID: 22750060 (Cited 11 times: as of 08-01-16)

35. Chen JJ, Sun YL, Tiwari AK, Xiao ZJ, Sodani K, Vispute SG, Yang DH, Chen SD and Chen ZS. PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of MRP7 (ABCC10) transporter. Cancer Sci. 2012 May 11. doi: 10.1111/j.1349-7006.2012.02328.x. [Epub ahead of print] PMID: 22578167 (Cited 21 times: as of 08-01-16)

36. Li T, Yang Y, Cheng C, Tiwari AK, Sodani K, Zhao Y, Chen ZS, . N-biphenyl (terphenyl)-2,2-dichloroacet-amide analogues as anti-cancer drugs: design, synthesis and biological evaluation. Bioorg Med Chem Lett. 2012 Jul 23. ii: S0960-894X(12)00933-X. doi: 10.1016/j.bmcl. 2012.07.057. PMID: 23067553 (Cited 5 times: as of 08-01-16)

37. Sodani K, Tiwari AK, Dai CL, Patel A, Chen ZS. GW583340 and GW2974, Human EGFR and HER-2 inhibitors, reverse ABCB1- and ABCG2-mediated drug resistance. Biochem Pharmacol. 2012 Jun 15;83(12):1613-22. Epub 2012 Mar 7. PMID: 22414725 (Cited 31 times: as of 08-01-16)

38. Peng XX, Tiwari AK, Wu HC and Chen ZS. Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myeloid leukemia cells. Chin J Cancer. 2012 Feb;31(2):110-8. Epub 2011 Nov 18. PMID: 22098951 (Cited 14 times: as of 08-01-16)

39. Chen ZS and Tiwari AK. Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and human genetic diseases. FEBS J. 2011 Sep;278(18):3226-45. Epub 2011 Aug 1. PMID: 21740521 (Cited 139 times: as of 08-01-16) (Note: Top citation award 2011-2013)

40. Shi Z, Tiwari AK, Patel A, Fu LW. Chen ZS. Roles of sildenafil in enhancing drug sensitivity in cancer. Cancer Res, 2011 Jun 1;71(11):3735-8. Epub 2011 May 24. PMID: 21610107 (Cited 30 times: as of 08-01-16)

41. Ding PR, Tiwari AK, Ohnuma S, Lee JWKK, An X, Dai CL, Lu Q, Singh S, Talele TT, Ambudkar SV, Chen ZS. The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein. Submitted to Plos One, 2011 Apr 28;6(4):e19329. PMID: 21552528 (Cited 52 times: as of 08-01-16)

42. Shi Z, Tiwari AK, Shukla S, Robey RW, Singh S, Kim IW, Bates SE, Peng XX, Abraham I, Ambudkar SV, Talele TT, Fu LW, Chen ZS. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res, 2011 Apr 15;71(8):3029-41. Epub 2011 Mar 14. PMID: 21402712 (Cited 86 times: as of 08-01-16)

43. Peng XX, Shi Z, Tiwari AK, Damaraju VL, Fu L, Cass CE, Kruh GD and Chen ZS. Up-regulation of P-gp in human chronic myeloid leukemia cells with acquired resistance to 6-mercaptopurine. Oncol Lett, 2011 May-Jun 2 (3):549-56. (Cited 14 times: as of 08-01-16)


44. Tiwari AK, Sodani K, Dai CL, Ashby C, Chen ZS. Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy. Curr Pharm Biotechnol. 2011 Apr 1;12(4):570-94. PMID: 21118094 (Cited 117 times: as of 08-01-16) (Note: Top 5 most cited article in Curr Pharm Biotechnol)

45. Mi YJ, Liang YJ, Huang HB, Zhao HY, Wu CP, Wang F, Tao LY, Zhang CZ, Dai CL, Tiwari AK, Ma XX, To KKW, Ambudkar SV, Chen ZS, and Fu LW. Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters. Cancer Res 2010 Oct 15;70(20):7981-91. Epub 2010 Sep 28. PMID: 20876799 (Cited 103 times: as of 08-01-16)

46. Tiwari AK, Xin A, Chen ZS. The role of stem cell markers in multidrug resistance mediated by ABC transporters. Leukemia Res 34, 696–697, 2010 doi:10.1016/j.leukres.2009.12.007. PMID: 20061021 (Cited 5 times: as of 08-01-16)

47. An X*, Tiwari AK*, Sun Y, Ding PR, Ashby CR, and Chen ZS. BCR-ABL tyrosine kinase inhibitors in the treatment of philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res. 2010 Oct;34(10):1255-68. PMID: 20537386 (*Joint-First

Author) (Cited 143 times: as of 08-01-16) (Note: Top 10 most cited article in leukemia research)

48. Kuang YH, Shen T, Chen X, Sodani K, Hopper-Borge E, Tiwari AK, Lee JW, Fu LW and Chen ZS Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochem Pharmacol 2010 Jan 15;79(2):154-61. Epub 2009 Aug 29. PMID: 19720054 (Cited 67 times: as of 08-01-16)

49. Shen T, Kuang YH, Ashby CR, Lei Y, Chen A, Zhou Y, Chen X, Tiwari AK, Hopper-Borge E, Ouyang J and Chen ZS. Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). PLoS One 2009 Oct 20;4(10):e7520. PMID: 19841739 (Cited 55 times: as of 08-01-16)

50. Tiwari AK#, Sodani K, Chen ZS. Current advances in modulation of ABC transporter-mediated multidrug resistance in cancer. Invited review. International J of Pharml and Clin Res, 2009. 1(1): 1-6 (Cited 6 times: as of 08-01-16) (*Correspondence)

51. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR, Jr., Chen X and Chen ZS. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol 2009 Jul 15;78(2):153-61. Epub 2009 Apr 11. PMID: 19427995 (Cited 156 times: as of 08-01-16) (*Note: Top citation award from Elsevier for top cited article in biochemical pharmacology from 2009-2011) ** Also, 4th and 5th most hottest article at Sciencedirect.com from jun-dec 2009 http://top25.sciencedirect.com/subject/pharmacology-toxicology-and-pharmaceutical-science/20/journal/biochemical-pharmacology/00062952/archive/22/

52. Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ and Fu LW. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett 2009 Jun 28;279(1):74-83. Epub 2009 Feb 18. PMID: 19232821 (Cited 79 times: as of 08-01-16)




53. Shi Z, Tiwari AK, Shukla S, Robey RW, Kim IW, Parmar S, Bates SE, Si QS, Goldblatt CS, Abraham I, Fu LW, Ambudkar SV and Chen ZS. Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol 2009 Mar 1;77(5):781-93. Epub 2008 Nov 18. PMID: 19059384 (Cited 50 times: as of 08-01-16)

54. Dai CL*, Tiwari AK*, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR, Jr., Huang Y, Robey RW, Liang YJ, Chen LM, Shi CJ, Ambudkar SV, Chen ZS and Fu LW. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 2008 Oct 1;68(19):7905-14 PMID: 18829547 (*Joint-First Author). (Cited 225 times: as of 08-01-16)

55. Peng XX, Shi Z, Damaraju VL, Huang XC, Kruh GD, Wu HC, Zhou Y, Tiwari AK, Fu L, Cass CE and Chen ZS. Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. Leuk Res 32:799-809, 2008. PMID: 17996297 (Cited 43 times: as of 08-01-16)

Papers in preparation and submission

1. Balch C, Ramapuram JB and Tiwari AK. The epigenomics of embryonic signaling

pathways in chemo-resistant colon cancer. (Under review – Biochemical Biophysical

Research Communications)

2. Amawi H, Ashby C, Tiwari AK. Cancer chemoprevention through dietary flavonoids:

Whats limiting? (Under review – Chinese Journal of Cancer)

3. Manivannan E, Amawi H, Hussein N, Karthikeyan Fetcenko AC, Narayana Moorthy

NSH , Trivedi P and Tiwari AK. Design and discovery of novel silybin analogs as

antiproliferative compounds using a ring disjunctive - based, natural product lead

optimization approach. (Under review – European Journal of Medicinal Chemistry)

4. Miller SA, White JA, Chowdhary R, Gales DN, Tameru B, Tiwari AK, Samuel T.

Consumption of whole grape powder attenuates basal NF-kB signaling and reduces

inflammatory cytokine secretion in a mouse model of inflammation. (Under Review –

Journal of Nutritional Biochemistry)

5. Narayanan NK, Kunimasa K, Miller G, Zambrinis C, Zanzonico P, Longo V, Wolf FR,

Tani H, Chiriboga LA, Mark A, Mara L, Ashby CR, Ikeda C, Tomida A, Tiwari AK and

Narayanan B. Dietary melinjo seed extract suppresses oncogenetic Kras-driven

pancreatic intraepithelial neoplasia progression to pancreatic ductal adenocarcinoma in

LSL-KrasG12D/+/p48-Cre mice (Submitted to Oncotarget).

6. Bedi D, McIntosh K, Tiwari AK and Yates C. Increased expression of neuronal adhesion

molecule, neuroligin’s in basal type breast cancer. (To be submitted to PlosOne)


7. Trivedi, PhD; Amit K. Tiwari, PhDAmawi H, Hussein N, Chandrabose K, Trivedi P and

Tiwari AK. Novel silybin analogue inhibits EMT/beta-catenin/Wnt pathways in

resistant ovarian cancer therapy. (To be submitted to Oncotargets)

8. Buckley T, Chandrabose K, Mittal R, Guedes A, Okumu L, Calston A, Trivedi P and Tiwari AK#. Anticancer activities of novel Phosphodiesterase-5 antagoists against prostate cancer and their mechanisms. (To be submitted to Neoplasia)

9. Tiwari AK# and Ashby CR. Redundant functions of ABC drug transporters. Review (To be submitted to Drug Resistance Updates)

10. Wang Z, Tiwari AK and Gallo JM. Evaluation of Abcc2 and Abcc3 transporters in the oral bioavailability of methotrexate. (To be submitted to Drug Metab and Dispos)

11. Tiwari AK, Sodani K and Chen ZS. Pharmacokinetic-Pharmacodynamic driven anticancer drug development of a novel N-biphenyl (terphenyl)-2,2-dichloroacet-amide analogue A-25. (To be submitted to Cancer Sci)

12. Zeng C, He F, Xia C, Zhang H, Zhang R, Tiwari AK and Xiong Y. Identification and characterization of active components in shenmai injections which differentially affects CYP3A4-mediated midazolam 1’-hydroxylation and 4-hydroxylation. (To be submitted to Drug Metabolism and Disposition)

INVITED TALKS (Selected)

1. Amit K. Tiwari – “Advances in triple negative breast cancer therapy” 1st Annual Breast Cancer Summit at St. Rita’s Medical Lima, Ohio, September 29, 2016,

2. Amit K. Tiwari – “Drug Resistance: Can we get rid of ‘em” Graduate Students Seminar Series, Rajiv Gandhi Prodyogik Vishwavidyalaya, M.P. India – Feb 16th, 2016

3. Amit K. Tiwari – “Avenues and Challenges to Current Chemotherapy Development” International Conference on Emerging Frontiers in Drug Discovery and Development. Rajiv Gandhi Prodyogik Vishwavidyalaya, M.P. India – Feb 19th, 2016 (Eminent Guest Speaker)

4. Amit K. Tiwari – “Pharmaceutical Sciences as a Career Option for STEM majors” for the 2015 Research Experience for Undergraduate (REU), The Center for Nanobiotechnology Research, Alabama State University, Al– July 6th, 2015.

5. Amit K. Tiwari – Implications of efflux transporters in animal chemotherapeutics. Animal Science and College of Veterinary Medicine, Tuskegee University, Tuskegee, Al,– July 7th, 2015.

6. Amit K. Tiwari – Challenges and future directions of targeted anticancer drug discovery. Ohio State University, Department of Surgery and Medicine, Columbus, OH – July 14th, 2015.

7. Amit K. Tiwari – Targeted anticancer drug discovery and development. Anatrace Pharmaceuticals, Toledo, OH – July 24th, 2015.


8. Amit K. Tiwari – Anticancer drug development: Integrating Pharmacokinetic/ Pharmacodynamic approaches with systems biology. Fairleigh Dickinson University, Florham Park, NJ – October 9th, 2014.

9. Amit K. Tiwari – Polymorphic alterations in efflux transporters affect anticancer disposition. GMaP Maryland Conference invited by John’s Hopkins University, Bethesda, MD – June 18-19th, 2014.

10. Amit K. Tiwari – Implications of efflux transporters in anticancer therapy and resistance. Alabama State University, Montgomery, Al - Feb, 27th, 2014.

11. Amit K. Tiwari - Complimentary roles of efflux transporters in anticancer disposition. Mitchell Cancer Institute, University of South Alabama, Mobile, Al July, 23rd, 2013.

12. Amit K. Tiwari - Redundant functions of ABC transporters in topotecan disposition. Dept of Pharmacology and Systems Therapeutics. Mount Sinai School of Medicine, NY, Dec. 4th 2012.

13. Amit K. Tiwari - Overlapping functions of efflux transporters in drug disposition. Tuskegee University, AL, Nov. 30th 2012.

14. Amit K. Tiwari - Nilotinib (Tasigna®) reverses ABCB1- and ABCG2-mediated drug resistance by inhibiting their efflux function. Albert Einstein College of Medicine, Bronx, NY. March 16, 2011

15. Amit K. Tiwari - PDE5 inhibitors as modulators of MDR. 7th National ABC transporters meeting, NCI, NIH, Bethesda, MD 20892, September 14-15, 2010

16. Amit K. Tiwari - Differential Effects of the EGFR Tyrosine Kinase Inhibitor AG1478 on the Function of ABCB1 and ABCG2. 5th Northern American ABC transporters meeting, NCI, NIH, Bethesda, MD 20892; September 24-26th, 2008

17. Amit K. Tiwari - Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. 4th Northern American ABC transporters meeting, NCI, NIH, Bethesda, MD 20892; October 3rd-5th, 2007

18. Amit K. Tiwari - “Bifidogenic effect and power of immunity”, Nestle Nutrition Symposium, Bareily, U.P, India; 4th July, 2006

ABSTRACTS AND POSTER PRESENTATIONS

1. Chvatal A, Al-zhrani R, AmbrusR, Szabó-Révész P, Tiwari AK, and Boddu SHS. Cytotoxicity and aerodynamical testing of spray dried meloxicam forms for inhalation. 6th FIP Pharmaceutical Sciences World Congress 2017, Stockholm, Sweden, 21-24 May 2017.

2. Gumireddy A, Chauhan HV, Chauhan DK, Christman JN, Amawi H, and Tiwari AK. “Formulation of Soluble Binary and Novel Ternary Amorphous Complexes for Anticancer Activity”. Poster presented at AAPS annual meeting, exposition and

conference, Colorado on November 13-17, 2016


3. Amawi H, Hussein N, Fetcenko A, Chandrabose K, Manivannan E, Chauhan H, Mittal R, Trivedi P, and Tiwari AK. “Design and pharmacological development of novel silybin analogues as potent and selective antiproliferative agents”. Poster presented at AAPS

annual meeting, exposition and conference, Colorado on November 13-17, 2016

4. Hussein N, Amawi H, Charles Jr A, Chandrabose K, Mittal R, Trivedi P, and Tiwari AK. “Differential Effects of Dopamine D3 Antagonists in Modulating ABCG2 Mediated MDR”. Celebrating 30 Years of Research on Multidrug Resistance and ABC Transporters symposium, National Cancer Institute, NIH, Bethesda, MD, September 21-23, 2016.

5. McIntosh K, Amawi H, Mittal R, Hussein N, and Tiwari AK. “Redundant functions of ABC transporters in anticancer disposition”. Celebrating 30 Years of Research on Multidrug Resistance and ABC Transporters symposium, National Cancer Institute, NIH, Bethesda, MD, September 21-23, 2016.

6. Hussein N, Amawi H, Charles Jr A, Chandrabose K, Mittal R, Trivedi P and Tiwari AK. “Dopamine D3 antagonists reverse ABCG2 mediated MDR and enhance anticancer toxicity”. ECAT (Emerging health Care and Advancement in Toxicology) International

Conference, Toledo, OH September 8-10, 2016. (Best poster presentation award).

7. Amawi H, Chen J, Balch C, McIntosh K, Karthikeyan C, Trivedi P and Tiwari AK. Targeting chemo-resistant colon cancer by inhibiting embryonic resistance pathways. Experimental and Molecular Therapeutics, AACR Annual Meeting 2016 in New Orleans, Louisiana April 16-April 20.

8. Amawi H and Tiwari AK. Colon cancer chemoprevention by inhibiting embryonic signaling pathways. 7th Annual Midwest Graduate Research Symposium, The

University of Toledo, Ohio: Saturday, April 9th, 2016; Oral Talk

9. Amawi H and Tiwari AK. Colon cancer chemoprevention by plant derived synthetic analogues. Elevator Talk, Pharmaceutical Sciences Graduate Student Council (PSGSC)

Symposium; The University of Toledo, Ohio: April 1, 2016; Oral Talk (2rd Prize – Oral talk)

10. Nusbaum AC, McIntosh K, Malla R, Kirwen EM, Nyinawabera A, Karthikeyan C, Faridi

J, Trivedi P, and Tiwari AK. 2-(phenyl)-3H-benzo[d]imidazole-5-carboxylic acids:

Development of novel therapeutic agents against breast cancer. Ohio Valley Chapter of

the Society of Toxicology (OVSOT); Annual Meeting: Nov 13, 2015; Poster presentation

11. Kirwen EM, Nusbaum AC, Amawi H, McIntosh K, Malla R, Chen J, Nyinawabera A,

Karthikeyan C, Faridi J, Trivedi P, and Tiwari AK. (2E,5E) -5-(3-hydroxy-4-

methoxybenzylidene) -2-(phenylimino) thiazolidin-4-one: Development of Novel

Therapeutic Agents against Breast Cancer. Ohio Valley Chapter of the Society of

Toxicology (OVSOT); Annual Meeting: Nov 13, 2015; Poster presentation

12. Pondugula SR, Abbott KL, Flannery PC, Tiwari AK. Zosuquidar, an MDR1 inhibitor, activates human PXR to induce CYP3A4 and MDR1 gene expression. International Society for Study of Xenobiotics Meeting, Orlando, Florida, USA (October 18-22, 2015).


Published in Drug Metabolism Reviews. Vol. 48. 2-4 Park Square, Milton Park, Abingdon Or14 4rn, Oxon, England: Taylor & Francis Ltd, 2016.

13. Chaudhury CS, Abbott KL, Flannery PC, Tiwari AK, Pondugula SR. Gefitinib, a clinically-used tyrosine kinase inhibitor, inhibits the transcriptional activity of pregnane X receptor in human hepatocytes. Auburn University Research Initiative In Cancer Meeting, Opelika, AL (August 28-29, 2015).

14. Chen J, Amawi H, McIntosh K, Karthikeyan C, Trivedi P, Pondugula PR and Tiwari AK.

Pyrimido[1", 2":1,5]pyrazolo[3,4-b]quinolines reverses ABCG2-mediated multi-drug resistance in cancer. Ohio Valley Chapter of the Society of Toxicology (OVSOT);

Annual Meeting: Nov 13, 2015; Poster presentation

15. Suswam EA, Putcha BDK, Tiwari AK, Jadhav T, Walker KD, Harkins L, Amer S, Eltoum IE, Bae S, Manne U. Molecular and cellular localization profiles of tristetraprolin in colorectal cancer: Implications for tumor progression in diverse patient populations. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association

for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4953. doi:10.1158/1538-7445.AM2015-4953

16. Narayanan NK, Kunimasa K, Tian D, Horton L, Dolgaev I, Heguy A, Miller G, Tiwari

AK, Narayanan BA. Gnetin C, a novel resveratrol dimer, targets pancreatic cancer metabolism. AACR Special Conference on Pancreatic Cancer: Innovations in Research

and Treatment; May 18-21, 2014; New Orleans, LA , article in Cancer Research 75(13 SUPPLEMENT):B57-B57 · July 2015; doi: 10.1158/1538-7445.PANCA2014-B57

17. Lee C, Chandrabose K, Mittal R, Pondugula S, Trivedi P and Tiwari AK#. Development of novel therapeutic agents against colorectal cancer. Annual Biomedical Research

Conference for Minority Students, Nov 12-15th 2014, San Antonio, TX

18. Buckley T, Saddler M, Herring S, Chandrabose K, Lee C, Pondugula S, Trivedi P and

Tiwari AK#. Chemosensitizing Difficult To Treat Tumors by Reversing ABCG2-Mediated Multidrug Resistance. Annual Biomedical Research Conference for Minority Students,

Nov 12-15th 2014, San Antonio, TX

19. Buckley T, Wirtu G, Mittal R, Chowdhary R, Vig K, Chen ZS and Tiwari AK#.

“Enhancing delivery of tyrosine kinase inhibitors in drug resistant tumors” George Washington Carver Conference, October 31st 2014, Tuskegee University, AL

20. Jones V, Chandrabose K, Lee C, Saddler M, Robinson T, Trivedi P and Tiwari AK#. Novel 3-((2-chloroquinolin-3-yl)methylene)indolin-2-one derivatives produces potent anticancer effects against ovarian cancer in vitro. Phi-Zeta Research conference, 15th

Biomedical Symposium, Sept 17-18th 2014, Tuskegee University, AL

21. Hassan H, Tiwari AK, Min B, Reddy, G, Hinton A and Abdela W. Use of extracts of Citrus sinensis as antimicrobial agents for foodborne zoonotic pathogens and spoilage bacteria. 15th Biomedical Symposium, Sept 17-18th 2014, Tuskegee University, AL (Oral talk)

22. Lee C, Chandrabose K, Mittal R, Pondugula S, Trivedi P and Tiwari AK#. Development of novel therapeutic agents against colorectal cancer. Phi-Zeta Research conference, 15th


Biomedical Symposium, Sept 17-18th 2014, Tuskegee University, AL (2rd Prize – Oral talk)

23. Saddler M, Herring S, Chandrabose K, Lee C, Pondugula S, Trivedi P and Tiwari AK#.

Targeted approach to overcome ABCG2-mediated drug resistance in cancer. Phi-Zeta

Research conference, 15th Biomedical Symposium, Sept 17-18th 2014, Tuskegee University, AL (3rd Prize – Oral talk)

24. Gruber NM, Tiwari AK, Sanglard LP, Samuel T, Bedi D, Wirtu G. Acetyl Co-A Carboxylase (ACC) inhibitor sensitizes an anticancer agent in canine and human mammary neoplasia cells. 15th Annual Merial-NIH Veterinary Scholars Symposium "One Health" July 31 - August 3, 2014, Cornell University CVM, Ithaca, NY

25. Jones V, Chandrabose K, Lee C, Saddler M, Robinson T, Trivedi P and Tiwari AK#.

Novel 3-((2-chloroquinolin-3-yl)methylene)indolin-2-one derivatives produces potent anticancer effects against ovarian cancer in vitro. 15th Annual Merial-NIH Veterinary Scholars Symposium "One Health" July 31 - August 3, 2014, Cornell University CVM, Ithaca, NY

26. Moore J, Chandrabose K, Herring S, Lee C, Buckley T, Pondugula S, Mittal R, Trivedi P and Tiwari AK#. Targeting ABCG2-transporters to overcome drug resistance in cancer. IBS-REU summer research program. July 30th, 2014, Tuskegee University, AL.

27. Herring S, Saddler M, Chandrabose K, Lee C, Pondugula S, Trivedi P and Tiwari AK#.

Targeted approach to overcome ABCG2-mediated drug resistance in cancer. MSE-RISE summer research program, July 28th 2014, Tuskegee University, AL

28. Tiwari AK, Moore J, Herring S, Lee C, Chandrabose K, Pondugula S, and Trivedi P. Novel chemo-adjuvants to overcome multidrug resistance in cancer. Health Disparity Research and Training Program, Summer Institute, July 22-23, 2014, held at University of Alabama at Birmingham, AL (2nd Best Poster Award)

29. Buckley T, Wirtu G, Mittal R, Chowdhary R, Vig K, Chen ZS and Tiwari AK#.

“Enhancing delivery of tyrosine kinase inhibitors in drug resistant tumors” Internatonal Nano-Bio Summit, October 17th-18th, 2013, Alabama State University, AL

30. Buckley T, Brockett E, Chen ZS and Tiwari AK#. “Defining the roles of efflux transporters in tyrosine kinase inhibitors drug disposition” ABRCMS meeting November 13th 2013, Nashvile, Tenessee

31. Tiwari AK#, Buckley T, Patel A, Chen ZS and Gallo JM. “Complimentary functions of efflux transporters in anticancer elimination” 10th Northern American ABC transporters

meeting, NCI, NIH, Bethesda, MD 20892; September 18th, 2013

32. Tiwari AK#, Buckley T, Potts H, Piazza TJ and Gallo JM. “Polymorphic alterations in efflux transporters affect anticancer disposition” 14th Biomedical Symposium, Sept. 16-18, 2013, Tuskegee University, Tuskegee, AL

33. Sodani K, Tiwari AK, Dai CL, Abuznait AH, Xiao ZJ, Patel A, Kaddoumi A, Ashby CR, Chen ZS. “Sildenafil potentiates the anticancer activity of paclitaxel in ABCB1-mediated multidrug resistance xenograft mode” 104th American Association for Cancer Research

(AACR) 2013, Washington DC


34. Patel A, Tiwari AK, Chufan EE, Sodani K, Anreddy N, Singh S, Ambudkar SV, Stephani R and Chen ZS. PD17384, human VEGFR inhibitor, reverses ABCB1 mediated drug resistance in cancer cells. 2013, Gorden Research Conference: Multi-Drug Efflux Systems, Ventura, CA,

35. Chitranshi N, Tiwari AK, and Tripathi PK. Investigating the function of single nucleotide polymorphism (SNPs) in CTSB gene (cathepsin B): a computational approach. Proceedings of the 7th conference of the Hellenic Society for Computational Biology & Bioinformatics - HSCBB12 FORTH, Heraklion, Crete, Greece, Oct. 4-6, 2012 (also selected for oral presentation)

36. Sodani K, Tiwari AK, and Chen ZS. Nilotinib potentiates anticancer sensitivity in murine multidrug resistance xenograft models. 9th North American ABC workshop. NCI, NIH, Bethesda, MD 20892; September 27-28, 2012. (also selected for Oral presentation)

37. Sodani K, Tiwari AK, Dai CL, Patel A, Chen ZS. GW583340 and GW2974, Human EGFR and HER-2 inhibitors, reverse ABCB1- and ABCG2-mediated drug resistance. 103rd

American Association for Cancer Research (AACR) 2012, Chicago IL

38. Chen ZS, Sun YL, Chen JJ, Tiwari AK, Fu LW, and Dai CL. Screening for compounds that reverse MRP7-mediated multidrug. FEBS-ABC2012 - 4th FEBS Special Meeting on ABC

Proteins, March 3-9, 2012, Innsbruck, Austria

39. Chen JJ, Zhang DM, Bhatnagar J, Tiwari AK, Chen WM, Ambudkar SV, Chen SD, Ye CW and Chen ZS. B2B1, one of 23-hydroxybetulinic acid analogs, can modulate ABC transporters mediated MDR. 8th North American ABC workshop. NCI, NIH, Bethesda, MD 20892; Sept. 28-29, 2011, NCI-Frederick, Maryland. (Oral presentation)

40. Patel A, Tiwari AK, Sodani K, Singh S, Vispute S, Chen ZS. PD173074, a selective FGFR1 and FGFR3 inhibitor, reverses ABCB-1-mediated multidrug resistance. 8th North

American ABC workshop. NCI, NIH, Bethesda, MD 20892; Sept. 28-29, 2011, NCI-Frederick, Maryland. (Oral presentation)

41. Chen ZS, Tiwari AK, Shi Z, Shukla S, Singh S, Chen JJ, Patel A, Ambudkar SV. PDE5 inhibitors reverse ABCB1- and ABCG2-mediated chemotherapeutic drug resistance in cancer. Gordon Research Conference-Multi-Drug Efflux Systems, June 12-17, 2011, Les Diablerets, Switzerland. (Oral presentation)

42. Tiwari AK, Shi Z, Shukla S, Singh S, Chen JJ, Patel A, Ambudkar SV, Chen ZS. A new function of Sildenafil (Viagra ™) as a multidrug resistance modulator. 2011 NJPhast

Scholarship awards, Hanover Marriot, NJ, USA May 19, 2011

43. Tiwari AK, Shi Z, Shukla S, Singh S, Talele TT, Ambudkar SV, Chen ZS. Reversal of ABCB1- and ABCG2-mediated drug resistance by sildenafil. Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1. 102nd American Assoc for Can Res (AACR), Orlando, FL, USA April 1-5, 2011

44. Tiwari AK, Sodani K, Wang S, Kuang YH, Chen X, Chen K, Ashby CR, Chen ZS. BCR-Abl tyrosine kinase inhibitor Nilotinib (Tasigna®) reverses ABCB1/Pgp- and ABCG2/BCRP-mediated multidrug resistance. 101st American Assoc for Can Res

(AACR), Washington, DC, USA April 17-22, 2010


45. Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW, Sunitinib reverses ABCG2/BCRP-mediated multidrug resistance by inhibiting its efflux activity 101st American Association for Cancer Research (AACR), Washington, DC, USA April 17-22, 2010

46. Sodani K, Kuang YH, Shen T, Vispute S. Tiwari AK, Lei Y. Lee JW, Chen X, Fu LW and Chen ZS. Tyrosine kinase inhibitors are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. 101st American Assoc for Can Res (AACR), Washington, DC, USA April 17-22, 2010

47. Sodani K, Tiwari AK, Kuang YH, Shen T, D’Ambra TM, Lei Y, Lee J, Chen X, Ashby CR, Chen ZS. Lapatinib, erlotinib, imatinib and nilotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. 6th North American ABC workshop. NCI,

NIH, Bethesda, MD 20892; September 24-25, 2009

48. Tiwari AK, Sodani K, Wang S, Kuang YH, Chen X, Chen K, Ashby CR, Chen ZS. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. 6th North American ABC

workshop. NCI, NIH, Bethesda, MD 20892; September 24-25, 2009

49. Dai CL, Wang YS, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR, Huang Y, Robey RW, Liang YJ, Chen LM, Shi CJ, Ambudkar SV, Chen ZS, Fu LW. Lapatinib could reverse ABCB1 and ABCG2 mediated-multidrug resistance in Vitro, ex-vivo and in Vivo but increase exposure of chemotherapeutic agent. 100th American Assoc for Can Res

(AACR), Denver, Colorado, USA April 18-22, 2009

50. Chen ZS, Tiwari AK, Shi Z, Dai CL, Shukla S, Wu CP, Wang SR, Abraham I, Sodani K, Ashby CR, Kuang YH, Robey RW, Fu LW, Bates SE, Ambudkar SV. Tyrosine kinase inhibitors as modulators of multidrug resistance in cancer. Multidrug Resistance & ABC

Transporters Conference. Baltimore, Maryland USA, November 5th, 2009

51. Dai CL, Tiwari AK, Wu C, Su XD, Liu DG, Huang Y, Liang YJ, Chen LM, Shi CJ, Ashby CR, Chen ZS, Ambudkar SV, Zhang JY, Robey RW, Bates SE, Fu LW. Reversal of Multidrug Resistance ABCB1 and ABCG2 by Lapatinib. 5th Northern American ABC

transporters meeting, NCI, NIH, Bethesda, MD 20892; September 24-26, 2008

52. Tiwari AK, Shi Z, Parmar S, Shukla S, Robey RW, Kim IW, Bates SE, Si QS, Goldblatt CS, Abraham I, Shao N, Chen YM, Zhang A, Fu LW, Ambudkar SV, Chen ZS. Differential Effects of the EGFR Tyrosine Kinase Inhibitor AG1478 on the Function of ABCB1 and ABCG2. 99th American Association for Cancer Research (AACR), San Diego, CA, USA April 12-16, 2008

53. Shi Z, Peng XX, Kim IW, Shukla S, Tiwari AK, Si QS, Robey RW, Bates SE, Wang S, Chim C, Shen T, Ashby CR, Fu LW, Ambudkar SV, Chen ZS. Reversal of ABCB1- and ABCG2-mediated MDR by erlotinib (tarceva, OSI-774). 99th American Assoc for Can Res

(AACR), San Diego, CA, USA April 12~16, 2008

54. Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Tiwari AK, Ashby CR, Jr., Fu LW, Ambudkar SV and Chen ZS Erlotinib (Tarceva, OSI-774) Antagonizes ABCB1 (P-glycoprotein)- and ABCG2-mediated Drug Resistance. The 4th North

American ABC workshop, NCI, NIH, Bethesda, MD, USA October 4-5, 2007


55. Shen T, Tiwari AK, Shi Z, Abraham I, Peng XX, Kim IW, Jain S, Ashby CR, Fu LW, Youssef D, Sayed KL, Ambudkar SV, Chen ZS. Development of Sipholane Triterpenes as Modulators of Multidrug Resistance in Cancer. 4th Northern American ABC transporters

meeting, NCI, NIH, Bethesda, MD 20892; October 3-5, 2007

56. Tiwari AK, Peng XX, Shi Z, Damaraju VL, Huang XC, Kruh GD and Chen ZS. “Characterization of human T cell line with acquired drug resistance to 6-Mercaptopurine”; College of Pharmacy and Allied Health Sciences, St. John’s

University, Jamaica, NY 11439 October 23, 2007

57. Shi Z, Jain S, Kim IW, Peng XX, Tiwari AK, Abraham I, Youssef DT, Fu LW, El Sayed K, Ambudkar SV and Chen ZS “Development of Sipholane Triterpenes as modulators of multidrug resistance in cancer”; College of Pharmacy and Allied Health Sciences, St.

John’s University, Jamaica, NY 11439 October 23, 2007

amit k. tiwari, ph.d. - biomedical and pharmacology...

Documents